Cargando…
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients
The detection of somatic driver mutations by next-generation sequencing (NGS) is becoming increasingly important in the care of advanced melanoma patients. In our study, we evaluated the NGS results of 82 melanoma patients from clinical routine in 2017. Besides determining the tumor mutational burde...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563780/ https://www.ncbi.nlm.nih.gov/pubmed/32825510 http://dx.doi.org/10.3390/cancers12092359 |
_version_ | 1783595565027688448 |
---|---|
author | Hilke, Franz J. Sinnberg, Tobias Gschwind, Axel Niessner, Heike Demidov, German Amaral, Teresa Ossowski, Stephan Bonzheim, Irina Röcken, Martin Riess, Olaf Garbe, Claus Schroeder, Christopher Forschner, Andrea |
author_facet | Hilke, Franz J. Sinnberg, Tobias Gschwind, Axel Niessner, Heike Demidov, German Amaral, Teresa Ossowski, Stephan Bonzheim, Irina Röcken, Martin Riess, Olaf Garbe, Claus Schroeder, Christopher Forschner, Andrea |
author_sort | Hilke, Franz J. |
collection | PubMed |
description | The detection of somatic driver mutations by next-generation sequencing (NGS) is becoming increasingly important in the care of advanced melanoma patients. In our study, we evaluated the NGS results of 82 melanoma patients from clinical routine in 2017. Besides determining the tumor mutational burden (TMB) and annotation of all genetic driver alterations, we investigated their potential as a predictor for resistance to immune checkpoint inhibitors (ICI) and as a distinguishing feature between melanoma subtypes. Melanomas of unknown primary had a similar mutation pattern and TMB to cutaneous melanoma, which hints at its cutaneous origin. Besides the typical hotspot mutation in BRAF and NRAS, we frequently observed CDKN2A deletions. Acral and mucosal melanomas were dominated by CNV alterations affecting PDGFRA, KIT, CDK4, RICTOR, CCND2 and CHEK2. Uveal melanoma often had somatic SNVs in GNA11/Q and amplification of MYC in all cases. A significantly higher incidence of BRAF V600 mutations and EGFR amplifications, PTEN and TP53 deletions was found in patients with disease progression while on ICI. Thus, NGS might help to characterize melanoma subtypes more precisely and to identify possible resistance mechanisms to ICI therapy. Nevertheless, NGS based studies, including larger cohorts, are needed to support potential genetic ICI resistance mechanisms. |
format | Online Article Text |
id | pubmed-7563780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75637802020-10-27 Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients Hilke, Franz J. Sinnberg, Tobias Gschwind, Axel Niessner, Heike Demidov, German Amaral, Teresa Ossowski, Stephan Bonzheim, Irina Röcken, Martin Riess, Olaf Garbe, Claus Schroeder, Christopher Forschner, Andrea Cancers (Basel) Article The detection of somatic driver mutations by next-generation sequencing (NGS) is becoming increasingly important in the care of advanced melanoma patients. In our study, we evaluated the NGS results of 82 melanoma patients from clinical routine in 2017. Besides determining the tumor mutational burden (TMB) and annotation of all genetic driver alterations, we investigated their potential as a predictor for resistance to immune checkpoint inhibitors (ICI) and as a distinguishing feature between melanoma subtypes. Melanomas of unknown primary had a similar mutation pattern and TMB to cutaneous melanoma, which hints at its cutaneous origin. Besides the typical hotspot mutation in BRAF and NRAS, we frequently observed CDKN2A deletions. Acral and mucosal melanomas were dominated by CNV alterations affecting PDGFRA, KIT, CDK4, RICTOR, CCND2 and CHEK2. Uveal melanoma often had somatic SNVs in GNA11/Q and amplification of MYC in all cases. A significantly higher incidence of BRAF V600 mutations and EGFR amplifications, PTEN and TP53 deletions was found in patients with disease progression while on ICI. Thus, NGS might help to characterize melanoma subtypes more precisely and to identify possible resistance mechanisms to ICI therapy. Nevertheless, NGS based studies, including larger cohorts, are needed to support potential genetic ICI resistance mechanisms. MDPI 2020-08-20 /pmc/articles/PMC7563780/ /pubmed/32825510 http://dx.doi.org/10.3390/cancers12092359 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hilke, Franz J. Sinnberg, Tobias Gschwind, Axel Niessner, Heike Demidov, German Amaral, Teresa Ossowski, Stephan Bonzheim, Irina Röcken, Martin Riess, Olaf Garbe, Claus Schroeder, Christopher Forschner, Andrea Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients |
title | Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients |
title_full | Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients |
title_fullStr | Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients |
title_full_unstemmed | Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients |
title_short | Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients |
title_sort | distinct mutation patterns reveal melanoma subtypes and influence immunotherapy response in advanced melanoma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563780/ https://www.ncbi.nlm.nih.gov/pubmed/32825510 http://dx.doi.org/10.3390/cancers12092359 |
work_keys_str_mv | AT hilkefranzj distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT sinnbergtobias distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT gschwindaxel distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT niessnerheike distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT demidovgerman distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT amaralteresa distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT ossowskistephan distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT bonzheimirina distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT rockenmartin distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT riessolaf distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT garbeclaus distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT schroederchristopher distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients AT forschnerandrea distinctmutationpatternsrevealmelanomasubtypesandinfluenceimmunotherapyresponseinadvancedmelanomapatients |